"Matei Bals" National Institute of Infectious Diseases,Clinical Trials department
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Streinu-Cercel, Adrian
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Checkmark [VIRTUAL] Improving the Accuracy of Non-Invasive Tests for Prediction of Cirrhosis in Chronic Hepatitis Delta: Insights from 230 Patients of the D-LIVR Study
Checkmark [VIRTUAL] Improving the Accuracy of Non-Invasive Tests for Prediction of Cirrhosis in Chronic Hepatitis Delta: Insights from 230 Patients of the D-LIVR Study
Checkmark [VIRTUAL] NONINVASIVE TESTS FOR DETECTION OF BIOPSY-PROVEN CIRRHOSIS IN CHRONIC HEPATITIS D INFECTED PATIENTS ARE SUBOPTIMAL
Recruiting
3
400
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc., EIGER BIOPHARMACEUTICALS, INC.
Hepatitis Delta Virus
12/22
04/23
NCT04652518: LYT-100 in Post-acute COVID-19 Respiratory Disease

Recruiting
2
168
Europe, US, RoW
LYT-100, Deupirfenidone, Placebo
PureTech, Clinipace Worldwide, Novotech (Australia) Pty Limited
Covid19
08/21
12/21

Download Options